10-Q · May 1, 2026
Encompass Health Corporation (EHC) reported strong Q1 2026 results, with net operating revenues increasing 9.0% year-over-year to $1.586 billion, surpassing estimates of $1.568 billion. Diluted EPS came in at $1.77,…
Earnings analysis · 10-Q
EHC earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
Encompass Health reported Q2 2026 revenue of $1.597 billion and diluted EPS of $1.55. Revenue increased approximately 0.4% sequentially and 9.4% year over year, while EPS declined 19.7% sequentially but rose 11.5% year…
Read full summary
Encompass Health reported Q2 2026 revenue of $1.597 billion and diluted EPS of $1.55. Revenue increased approximately 0.4% sequentially and 9.4% year over year, while EPS declined 19.7% sequentially but rose 11.5% year over year. The provided filing extract contains no segment, cash-flow, margin, balance-sheet, or quantitative guidance details, and reports no material changes to the prior 10-K risk factors.
Reported figures
- Earnings per share
- $1.55
What stood out
-
Revenue continued to grow
Revenue was $1.597 billion, up from $1.59 billion in Q1 2026 and $1.46 billion in Q2 2025, representing approximately 0.4% sequential growth and 9.4% year-over-year growth.
-
EPS up year over year
Diluted EPS was $1.55, compared with $1.93 in Q1 2026 and $1.39 in Q2 2025. EPS declined approximately 19.7% sequentially but increased 11.5% year over year.
-
Share repurchases remained active
The company repurchased 704,246 shares during the quarter at an average price of $103.81 per share, supporting per-share value but using capital for buybacks.
-
Repurchase authorization expanded
On July 23, 2026, the board reset the aggregate common-stock repurchase authorization to $1.0 billion, up from the previously cited $500 million authorization.
What to watch
-
No formal risk-factor update
Item 1A states that there have been no material changes from the risk factors in the 2025 Form 10-K. The filing instead points investors to the MD&A's “Executive Overview—Key Challenges” discussion for updates.
-
Expanded buyback capital commitment
The board reset the repurchase authorization to $1.0 billion on July 23, 2026. Although discretionary, deploying capital at that scale could reduce liquidity available for debt reduction, acquisitions, or other corporate needs.
-
Debt details not provided in extract
The filing includes an indenture dated May 29, 2026, following the company's issuance of senior notes. The provided text does not disclose the outstanding debt balance, maturity profile, or covenant headroom, limiting assessment of leverage risk.
Management's outlook
No quantitative outlook was included in the provided 10-Q text. The filing states that there were no material changes to the risk factors disclosed in the 2025 Form 10-K; outlook information may be in the earnings release or call.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.